TELO (Telomir Pharmaceuticals Inc.) stock: $0.71, $52.3M market cap, $5.2M cash, $47.1M EV, $50.8M fully diluted market cap. Next expected readout: May-27. Lead program: Zn-Telomir (Triple-Negative Breast Cancer (TNBC)), Phase 2. Data from Fully Diluted's biotech stocks database.
What they do
Our research strategy targets fundamental cellular processes associated with disease progression and functional decline, including metal-ion dysregulation, oxidative stress, epigenetic regulation, mitochondrial dysfunction, and telomere integrity.
Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.
Share structure
Common
68.8M
Pre-funded warrants
0.0M
Options
—
RSUs
—
Warrants
2.8M
Converts
0.0M
Conv preferred
0.0M
ESPP reserve
—
FDSO
71.6M
Cap table as of 2026-08-12.
Price history
Loading TELO daily closes…
Loading price history…
Next catalyst
Zn-Telomir · Jun 12 - Jul 24 in 7 mo · Phase 2 · Triple-Negative Breast Cancer (TNBC); Advanced Triple-Negative Breast Cancer; Metastatic Triple-negative Breast Cancer
Triple-Negative Breast Cancer (TNBC); Advanced Triple-Negative Breast Cancer; Metastatic Triple-negative Breast Cancer
—
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Preclinical · ActiveModality: small molecule (oral)
Aliases Telomir-1
Partnerships MIRALOGX, LLC (two exclusive license agreements, November 2022 and March 2025; 8% royalty on net sales plus minimum annual royalty; worldwide rights obtained following the March 2026 merger)
Indications
Advanced or metastatic triple-negative breast cancer(Preclinical)
Wilson's disease(Preclinical)
Other oncology and metabolic indications (prostate, pancreatic cancers; diabetes) under preclinical evaluation(Preclinical)
Catalysts
— 2026
Status note Lead investigational candidate. All findings to date are preclinical. Company plans to submit an IND in 2026 and, if effective, commence a Phase 1/2 clinical trial thereafter, subject to regulatory review and manufacturing/operational readiness.
Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Triple-Negative Breast Cancer (TNBC); Advanced Triple-Negative Breast Cancer; Metastatic Triple-negative Breast Cancer
—
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.